Targets › BCMA
71 programs from 49 companies in 140 trials: 90 Phase 1, 36 Phase 2, 12 Phase 3, 2 Phase 4; Oncology, Immunology, Hematology; next expected readout Dec 2026.
Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. (UniProt, Q02223)
Open in Phaseline: the race on BCMA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | Linvoseltamab anti-B-cell maturation antigen x anti-CD3 bispecific antibody | BCMA, GPRC5D, CD3E, TNFRSF17 | Phase 4 | Relapsed/Refractory Multiple Myeloma (RRMM); Relapsed and/or Refractory Multiple Myeloma (RRMM); Relapsed Refractory Multiple Myeloma (RRMM); High Risk Smoldering Multiple Myeloma (HR-SMM) … | Aug 2027 |
| Turun Song | BCMA x CD3 Bispecific Antibody BCMA x CD3 bispecific T-cell engager (BiTE) that engages B cells and plasma cells expressi | BCMA, CD3E | Phase 4 | Antibody Mediated Rejection After Kidney Transplantation | Dec 2029 |
| AbbVie | ABBV-383 (Etentamig) BCMA-directed bispecific antibody | BCMA | Phase 3 | Multiple Myeloma; Relapsed/Refractory Multiple Myeloma; Immunoglobulin Light Chain (AL) Amyloidosis | Feb 2027 |
| Roche | Cevostamab BCMA-directed bispecific antibody | BCMA | Phase 3 | Multiple Myeloma | Feb 2027 |
| AstraZeneca | AZD0120 BCMA/CD19 dual CAR T cell therapy | BCMA, CD19 | Phase 3 | Relapsed Refractory Multiple Myeloma; Newly Diagnosed Multiple Myeloma (NDMM); Newly Diagnosed Multiple Myeloma; Relapsed/Refractory Multiple Myeloma … | Oct 2027 |
| Johnson & Johnson (Janssen) | Ramantamig BCMAxGPRC5DxCD3 trispecific antibody | TNFRSF17, CD3E, BCMA, GPRC5D | Phase 3 | Multiple Myeloma | Dec 2027 |
| Gilead Sciences | anitocabtagene autoleucel BCMA-directed CAR-T cell therapy | BCMA | Phase 3 | Multiple Myeloma; Muscular Diseases | Jul 2028 |
| Dana-Farber Cancer Institute | Linvoseltamab Bispecific T cell engager targeting CD3 and BCMA | CD3E, BCMA | Phase 3 | Multiple Myeloma | Oct 2033 |
| Institute of Hematology & Blood Diseases Hospital, China | CM336 BCMA/CD3 bispecific antibody | BCMA, CD3E | Phase 2 | Solitary Bone Plasmacytoma; Systemic Light Chain Amyloidosis; POEMS Syndrome; Immune Thrombocytopenia (ITP) … | Dec 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | Equecabtagene autoleucel anti-BCMA CAR-T cell therapy | BCMA | Phase 2 | Plasma Cell Leukemia | Dec 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | YK-BB-002 anti-BCMA CAR-T cell therapy | BCMA | Phase 2 | Plasma Cell Leukemia | Dec 2026 |
| Keymed Biosciences Co.Ltd | CM336 BCMA/CD3 bispecific antibody | BCMA, CD3E, TNFRSF17 | Phase 2 | Primary Light-Chain Amyloidosis; Multiple Myeloma; Autoimmune Cytopenia; Autoimmune Bullous Disease | Dec 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | anti-BCMA CAR-T anti-BCMA CAR-T cell therapy | BCMA | Phase 2 | Multiple Myeloma | Dec 2026 |
| Hrain Biotechnology | Human BCMA Targeted T Cells Injection (BCMA CAR-T) BCMA-targeted CAR-T cell therapy | BCMA | Phase 2 | Multiple Myeloma | Jul 2027 |
| Daihong Liu | PD-1Ab21-BCMA CAR-T BCMA-targeting CAR-T cells secreting PD-1 antibody and interleukin-21 fusion protein | BCMA, PDCD1, IL21 | Phase 2 | Multiple Myeloma | Jul 2027 |
| Institute of Hematology & Blood Diseases Hospital, China | BCMA CAR-T Anti-BCMA CAR-T cell therapy | BCMA | Phase 2 | Multiple Myeloma, Newly Diagnosed; Multiple Myeloma, Plasma Cell Leukemia | Aug 2027 |
| Chinese PLA General Hospital | Anti-BCMA-CD19 CAR-T cells Dual-target CAR-T cell therapy targeting CD19 and BCMA antigens | BCMA, CD19 | Phase 2 | IgG4 Related Disease | Sep 2027 |
| iCell Gene Therapeutics | ICG318 BCMA-CD19 dual-targeting CAR-T cells with IL-15/IL-15 sushi domain | TNFRSF17, CD19, BCMA | Phase 2 | Systemic Lupus Erythematosus (SLE); Inflammatory Myopathy | Dec 2027 |
| Polina Stepensky | HBI0101 anti-BCMA CAR-T cell therapy | BCMA | Phase 2 | Multiple Myeloma, Refractory to Standard Treatment; Systemic Sclerosis (SSc) | May 2028 |
| The First Affiliated Hospital of Xiamen University | BCMA CAR-T cells BCMA-targeting CAR-T cell therapy | BCMA | Phase 2 | Multiple Myeloma | Dec 2028 |
| Institute of Hematology & Blood Diseases Hospital, China | QLS4131 BCMA/GPRC5D/CD3 trispecific antibody | BCMA, GPRC5D, CD3 | Phase 2 | Primary Plasma Cell Leukemia | Dec 2029 |
| Ting Chang, MD | CD19-BCMA Targeted CAR-T Dual CD19-BCMA targeted CAR-T cell therapy | CD19, BCMA | Phase 1 | Myasthenia Gravis | Dec 2026 |
| Nexcella | NXC-201 CAR-T anti-BCMA CAR-T cell therapy | BCMA | Phase 1 | Light Chain (AL) Amyloidosis | Dec 2026 |
| Lakefront Biotherapeutics West | OM336 Bispecific antibody targeting BCMA and CD3 | BCMA, CD3 | Phase 1 | AIHA - Warm Autoimmune Hemolytic Anemia; Sjogrens Disease | Dec 2026 |
| Essen Biotech | BCMA/CD19 CAR-T cells chimeric antigen receptor T cells targeting BCMA and/or CD19 | BCMA, CD19 | Phase 1 | Autoimmune Diseases | Dec 2026 |
| Chongqing Precision Biotech | BCMA targeted prime CAR-T cells anti-BCMA CAR-T cell therapy | BCMA | Phase 1 | Multiple Myeloma | Dec 2026 |
| Nanjing University School of Medicine | FKC289 Dual-targeted BCMA/CD19 CAR-T cell therapy | BCMA, CD19 | Phase 1 | Lupus Nephritis | Dec 2026 |
| Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | MK-4002 (HPN217) Bispecific antibody targeting BCMA and CD3 | BCMA, CD3E | Phase 1 | Multiple Myeloma in Relapse | Dec 2026 |
| Excyte Biopharma | YKST02 BCMA-CD3 bispecific antibody | BCMA, CD3E | Phase 1 | Relapsed or Refractory Multiple Myeloma | Dec 2026 |
| The First Affiliated Hospital of Soochow University | RN1201 Injection CD19 and BCMA-targeted allogeneic CAR-T cells | CD19, BCMA | Phase 1 | Multiple Myloma; Refractory Immune-mediated Platelet Transfusion Refractoriness | Jan 2027 |
| Institute of Hematology & Blood Diseases Hospital, China | universal allogeneic anti-CD19/BCMA CAR T-cells dual-targeting CAR-T cell therapy targeting CD19 and BCMA | CD19, BCMA | Phase 1 | Autoimmune Hemolytic Anemia | Jan 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | CD19/BCMA CAR-T cell therapy Dual-targeted CAR-T cell therapy against CD19 and BCMA | CD19, BCMA | Phase 1 | Systemic Lupus Erythematosus | Jan 2027 |
| Peter MacCallum Cancer Centre, Australia | JNJ-68284528 (Cilta-cel) Anti-BCMA CAR-T cell therapy | BCMA | Phase 1 | Extramedullary Myeloma | Jan 2027 |
| Gracell Biotechnologies (Shanghai) | GC012F BCMA/CD19 dual CAR-T cell therapy | TNFRSF17, CD19, BCMA | Phase 1 | Multiple Myeloma; Refractory Systemic Lupus Erythematosus; Relapsed/Refractory AL Amyloidosis | Feb 2027 |
| Kali Therapeutics | KT501 Monoclonal antibody targeting CD19, BCMA and CD3 to deplete B cells and plasma cells | CD19, BCMA, CD3 | Phase 1 | Rheumatoid Arthritis (RA) | Feb 2027 |
| Beijing GoBroad Hospital | umbilical cord blood CD19-BCMA CAR-T cells dual-targeted CAR-T cell therapy targeting CD19 and BCMA | CD19, BCMA, CD5, CD7 | Phase 1 | Refractory Lupus Nephritis; T-Cell Non-Hodgkin Lymphoma | Apr 2027 |
| iCell Gene Therapeutics | BCMA-CD19 cCAR T cells Dual-targeted CAR T cell therapy targeting BCMA and CD19 expressed on B cells and plasma c | BCMA, CD19 | Phase 1 | Multiple Myeloma in Relapse; Refractory Immune Cytopenia | Apr 2027 |
| Beijing GoBroad Hospital | Dual-targeting BCMA-CD19 CAR-T cell Dual-target CAR-T cell therapy targeting BCMA and CD19 | BCMA, CD19 | Phase 1 | Relapsed or Refractory Multiple Myeloma (RRMM) | May 2027 |
| Beijing GoBroad Hospital | Dual-targeting BCMA-GPRC5D CAR-T cell Dual-target CAR-T cell therapy targeting BCMA and GPRC5D | BCMA, GPRC5D | Phase 1 | Relapsed or Refractory Multiple Myeloma (RRMM) | May 2027 |
| The Children's Hospital of Zhejiang University School of Medicine | anti-BCMA/CD70 CAR-T cells CAR-T cell therapy targeting BCMA and CD70 | BCMA, CD70 | Phase 1 | Multi-Drug Resistant Nephrotic Syndrome | Jul 2027 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQB2934 Anti-CD3 × BCMA double-specific antibody (bispecific T-cell engager) | CD3, BCMA | Phase 1 | Multiple Myeloma | Oct 2027 |
| Xijing Hospital | S103 cells BCMA-directed CAR-T cell therapy | BCMA | Phase 1 | Multiple Sclerosis (MS) Primary Progressive | Nov 2027 |
| Hadassah Medical Organization | Naive HBI0101 CAR-T anti-BCMA CAR-T cell therapy | BCMA | Phase 1 | Relapsed/Refractory Multiple Myeloma (MM) | Dec 2027 |
| Essen Biotech | BCMA/GPRC5D CAR-T cells Chimeric Antigen Receptor T cells targeting BCMA and/or GPRC5D | BCMA, GPRC5D | Phase 1 | Multiple Myeloma | Dec 2027 |
| Xuzhou Medical University | anti-BCMA/FcRL5 CAR-T dual-targeted CAR-T cell therapy targeting BCMA and FcRL5 | BCMA, FCRL5 | Phase 1 | Multiple Myeloma | Dec 2027 |
| Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | anti-BCMA CAR-T cells Anti-BCMA CAR-T cell therapy | BCMA | Phase 1 | Multiple Myeloma Refractory | Feb 2028 |
| Institute of Hematology & Blood Diseases Hospital, China | UCAR T-cell universal allogeneic anti-CD19/BCMA CAR T-cells | CD19, BCMA | Phase 1 | Systemic Lupus Erythematosus | Feb 2028 |
| Institute of Hematology & Blood Diseases Hospital, China | BCMA CART Anti-BCMA chimeric antigen receptor T-cell therapy | BCMA | Phase 1 | Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions | Mar 2028 |
| Institute of Hematology & Blood Diseases Hospital, China | BCMA-CART anti-BCMA chimeric antigen receptor T cell therapy | BCMA | Phase 1 | Multiple Myeloma | Mar 2028 |
| Medical College of Wisconsin | FT836 CAR T cells CAR-T cells targeting BCMA (B-cell maturation antigen) | BCMA | Phase 1 | Relapse Multiple Myeloma | Mar 2028 |
| O&D BioTech Group | O&D-001 injection Chimeric antigen receptor T cell targeting BCMA and GPRC5D | BCMA, GPRC5D | Phase 1 | Relapsed or Refractory Multiple Myeloma | Mar 2028 |
| The Children's Hospital of Zhejiang University School of Medicine | anti-BCMA/CD70-CAR-T cells CAR-T cells targeting BCMA and CD70 | BCMA, CD70 | Phase 1 | CAR T Cell Therapy | Apr 2028 |
| Ting Chang, MD | S103 BCMA-directed CAR-T cell therapy | BCMA | Phase 1 | Myasthenia Gravis, Generalized | Apr 2028 |
| Xi'an No.3 Hospital | allogeneic cord blood-derived, dual-targeting CD19/BCMA CAR-T cells (UCAR-T) dual-targeting CD19/BCMA CAR-T cell therapy | CD19, BCMA | Phase 1 | Relapsed/Refractory Multiple Myeloma(MM) | Jul 2028 |
| Sheba Medical Center | CAR-BCMA anti-BCMA CAR-T cell therapy | BCMA | Phase 1 | Multiple Myeloma | Sep 2028 |
| Chongqing Precision Biotech | BCMA/CD70-targeted CAR-T Dual-targeted CAR-T cell therapy against BCMA and CD70 | BCMA, CD70 | Phase 1 | Juvenile Dermatomyositis (JDM) | Sep 2028 |
| National Institute of Allergy and Infectious Diseases (NIAID) | CART-BCMA Chimeric Antigen Receptor T cell targeting B cell maturation antigen | BCMA | Phase 1 | Kidney Transplant | Dec 2028 |
| Chinese PLA General Hospital | KSVCBD injection in vivo CAR-T therapy targeting CD19 and BCMA | CD19, BCMA | Phase 1 | Multiple Myeloma; Non-Hodgkin's Lymphoma | Dec 2028 |
| The Children's Hospital of Zhejiang University School of Medicine | UCAR T-cell Universal allogeneic anti-CD19/BCMA CAR T-cells | CD19, BCMA | Phase 1 | Autoimmune Diseases | Dec 2028 |
| Institute of Hematology & Blood Diseases Hospital, China | QT-019C universal allogeneic anti-CD19/BCMA CAR T-cells | CD19, BCMA | Phase 1 | SLE - Systemic Lupus Erythematosus | Jan 2029 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development | TQB2934 injection Bispecific antibody targeting BCMA and CD3 | BCMA, CD3E | Phase 1 | Systemic Light Chain Amyloidosis | Feb 2029 |
| Poseida Therapeutics | P-BCMA-ALLO1 allogeneic BCMA-targeted CAR-T cell therapy | BCMA | Phase 1 | Multiple Myeloma | Mar 2029 |
| University College, London | BCMA CAR T cells CAR T cells targeting BCMA | BCMA | Phase 1 | Multiple Myeloma | Mar 2029 |
| University College, London | BCMA/CD19 CAR T cells CAR T cells co-expressing BCMA and CD19 CARs | BCMA, CD19 | Phase 1 | Multiple Myeloma | Mar 2029 |
| Columbia University | 131I-apamistamab Anti-BCMA radioimmunconjugate (iodine-131 labeled monoclonal antibody) | BCMA | Phase 1 | Sickling Disorder Due to Hemoglobin S | Mar 2030 |
| Celyad Oncology | CYAD-211 Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell | BCMA | Phase 1 | Relapse/Refractory Multiple Myeloma | Feb 2037 |
| Shanghai AbelZeta | C-CAR088 BCMA-directed CAR-T cell therapy | BCMA | Phase 1 | Multiple Myeloma | Jul 2037 |
| Thomas Martin, MD | Manufactured Anti-BCMA CAR-T cells anti-BCMA chimeric antigen receptor T cell therapy | BCMA | Phase 1 | Refractory Multiple Myeloma | Aug 2038 |
| Dispatch Biotherapeutics | DISP-10 Combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (BCMA-dire | BCMA | Phase 1 | Colorectal Cancer | Apr 2046 |
| Institute of Hematology & Blood Diseases Hospital, China | C-CAR088 anti-BCMA CAR-T cell | BCMA | Phase 1 | Multiple Myeloma | – |
| AbbVie | TNB-383B BCMA x CD3 T-cell engaging bispecific antibody | BCMA, CD3E | Phase 1 | Multiple Myeloma | – |
Multiple Myeloma (50) Relapsed/Refractory Multiple Myeloma (4) Plasma Cell Leukemia (4) Systemic Light Chain Amyloidosis (2) Relapsed Refractory Multiple Myeloma (RRMM) (2) Multiple Myeloma, Newly Diagnosed (2) Systemic Lupus Erythematosus (2) Relapsed or Refractory Multiple Myeloma (RRMM) (2) Multiple Myeloma in Relapse (2) Relapsed or Refractory Multiple Myeloma (2) Autoimmune Diseases (2) Refractory Lupus Nephritis (2)
other (35), mixed (14), small molecule (9), protein or peptide (8), antibody (5)
Institute of Hematology & Blood Diseases Hospital, China (12) Beijing GoBroad Hospital (3) The Children's Hospital of Zhejiang University School of Medicine (3) Ting Chang, MD (2) Chinese PLA General Hospital (2) iCell Gene Therapeutics (2) Essen Biotech (2) AbbVie (2) University College, London (2) Chongqing Precision Biotech (2) Poseida Therapeutics (1) Sheba Medical Center (1) Regeneron Pharmaceuticals (1) Johnson & Johnson (Janssen) (1) Xijing Hospital (1) AstraZeneca (1) Lakefront Biotherapeutics West (1) Nanjing University School of Medicine (1) Polina Stepensky (1) Gracell Biotechnologies (Shanghai) (1)
CD19 (20) CD3E (10) GPRC5D (6) TNFRSF17 (5) CD3 (4) CD70 (3) PDCD1 (1) IL21 (1) CD5 (1) CD7 (1) FCRL5 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.